Activities
1. EB66® Cell line: Valneva proposes this EB66® Cell line, derived from duck embryonic stem cells, to biotechnology companies, as well as to pharmaceutical industry, for the production of therapeutic and prophylactic viral vaccines, virosomes, recombinant proteins and monoclonal antibodies with enhanced cytotoxic activity.
2.VIVA|SCREEN Technology: This technology offers solutions for the discovery, by high-throughput screening, of human B lymphocytes isolated, as well as for the generation, development and production of fully human monoclonal antibodies
